Correlations between major depressive disorder, splenic morphology, and immune function.
Zouqing Lin, Xiaoyan Xu, Kai Zhang, Tenglong Wang, Leiming Cao, Zhiqiang Wang, Guoqiang Wang
BMC Psychiatry May 12, 2025 DOI: 10.1186/s12888-025-06853-w (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Patients with first-episode or recurrent major depressive disorder and healthy controls matched in age and gender |
| Intervention | (S)-ketamine |
| Duration | 4-week intervention |
| Topics | Depression |
| Keywords | Micb Splenic morphology Immunology Ketamine therapy Spleen anatomy Psychiatric medicine |
| Citations | 3 |
| Key findings | Elevated MICB and splenic volume in MDD patients decreased after (S)-ketamine treatment, indicating a potential role for immune mechanisms in depression. |
Abstract
To analyze the symptoms, courses, and severities of depressive disorder, as well as the morphological changes in the spleens and related immune mechanisms, we recruited patients with first-episode or recurrent major depressive disorder (MDD) (patient group) and healthy controls (normal group) matched in age and gender. We measured their plasma MICB (pg/ml), ULBP1 (ng/ml), and splenic volume (cm3) at baseline. The patient group was randomly assigned to receive (S)-ketamine (study group) or saline (control group), and the above indices were collected again on the 4th weekend after administration. At baseline, both MICB and splenic volume were significantly higher in the patient group than in the normal group. A positive correlation was observed between MICB and splenic volume in the patient group. After (S)-ketamine administration, the elevated splenic volume and MICB levels decreased. These results suggest that the pathogenesis of MDD may involve abnormal MICB expression and splenic morphology. (S)-ketamine may ameliorate inflammation and enhance splenic function, thereby relieving MDD symptoms.
Comparable studies
Other randomized controlled trials on depression, most cited first.
Citations in the library
Cites 10
- Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial American Journal of Psychiatry August 28, 2013
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study Biological Psychiatry November 4, 2015
- Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochemical Pharmacology July 1, 2020
- Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. Journal of Affective Disorders November 14, 2019
- Ketamine's mechanism of action with an emphasis on neuroimmune regulation: can the complement system complement ketamine's antidepressant effects? Molecular Psychiatry September 1, 2024
and 5 more in the library